Impact of Empagliflozin on Cardiac Arrhythmias and Heart Rate Variability in Kidney Transplant Recipients.

Kenan Evren Öztop, Yusuf Can, Mahmud İslam, Taner Demirci, Gözde Cakırsoy Çakar, Necattin Fırat, Musa Pınar, Zafer Ercan, Emrah Akın, Salih Salihi, Ahmed Cihad Genç, Fatih Altıntoprak, Hamad Dheir
{"title":"Impact of Empagliflozin on Cardiac Arrhythmias and Heart Rate Variability in Kidney Transplant Recipients.","authors":"Kenan Evren Öztop, Yusuf Can, Mahmud İslam, Taner Demirci, Gözde Cakırsoy Çakar, Necattin Fırat, Musa Pınar, Zafer Ercan, Emrah Akın, Salih Salihi, Ahmed Cihad Genç, Fatih Altıntoprak, Hamad Dheir","doi":"10.1016/j.transproceed.2025.02.045","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>We aimed to investigate the effects of Empagliflozin on cardiac arrhythmias and heart rate variability in kidney transplant recipients (KTRs).</p><p><strong>Methods: </strong>Twenty-seven diabetic patients who underwent kidney transplantation between August 2020 and August 2023 were included. Patients with HbA1c >8% were received Empagliflozin treatment. A 24-hour Holter ECG monitoring was performed before and one year after beginning Empagliflozin. Holter ECGs were evaluated by a single cardiologist, comparing ventricular ectopic beats (VEB) and supraventricular ectopic beats (SEB) arrhythmias and heart rate variability parameters before and after one year of Empagliflozin treatment.</p><p><strong>Results: </strong>Twenty-seven patients completed the study, and the mean patient age was 56.1 ± 10 years. Fifteen of the patients (55.6%) were male. The mean duration since transplant before starting Empagliflozin was 62.8 ± 46.2 months. In follow-up, HbA1c decreased from 8.2% to 7.7%(P = .075), urine protein/creatinine ratio reduced from 0.437 ± 0.428 to 0.267 ± 0.146 gr/g (P = .056), and platelet count increased significantly (P = .004). After one year of treatment, the number of VEBs and SEBs in the patients decreased compared to pretreatment. They decreased from 173.5 ± 460.8 and 514.8 ± 265 beats before treatment to 125.1 ± 231.7 and 125.1 ± 231.7 beats after treatment, respectively, but did not reach statistical significance (P > .05). No significant changes were found in heart rate variability parameters (P > .05). No significant correlation was found between VEBs and SEBs and cardiac inflammation indicators (P > .05).</p><p><strong>Conclusion: </strong>This study, for the first time, investigated the effect of Empagliflozin on cardiac arrhythmias and heart rate variability in diabetic KTRs. Empagliflozin did not significantly affect cardiac arrhythmias and heart rate variability in KTRs.</p>","PeriodicalId":94258,"journal":{"name":"Transplantation proceedings","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation proceedings","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.transproceed.2025.02.045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: We aimed to investigate the effects of Empagliflozin on cardiac arrhythmias and heart rate variability in kidney transplant recipients (KTRs).

Methods: Twenty-seven diabetic patients who underwent kidney transplantation between August 2020 and August 2023 were included. Patients with HbA1c >8% were received Empagliflozin treatment. A 24-hour Holter ECG monitoring was performed before and one year after beginning Empagliflozin. Holter ECGs were evaluated by a single cardiologist, comparing ventricular ectopic beats (VEB) and supraventricular ectopic beats (SEB) arrhythmias and heart rate variability parameters before and after one year of Empagliflozin treatment.

Results: Twenty-seven patients completed the study, and the mean patient age was 56.1 ± 10 years. Fifteen of the patients (55.6%) were male. The mean duration since transplant before starting Empagliflozin was 62.8 ± 46.2 months. In follow-up, HbA1c decreased from 8.2% to 7.7%(P = .075), urine protein/creatinine ratio reduced from 0.437 ± 0.428 to 0.267 ± 0.146 gr/g (P = .056), and platelet count increased significantly (P = .004). After one year of treatment, the number of VEBs and SEBs in the patients decreased compared to pretreatment. They decreased from 173.5 ± 460.8 and 514.8 ± 265 beats before treatment to 125.1 ± 231.7 and 125.1 ± 231.7 beats after treatment, respectively, but did not reach statistical significance (P > .05). No significant changes were found in heart rate variability parameters (P > .05). No significant correlation was found between VEBs and SEBs and cardiac inflammation indicators (P > .05).

Conclusion: This study, for the first time, investigated the effect of Empagliflozin on cardiac arrhythmias and heart rate variability in diabetic KTRs. Empagliflozin did not significantly affect cardiac arrhythmias and heart rate variability in KTRs.

恩格列净对肾移植受者心律失常和心率变异性的影响。
目的:研究恩格列净对肾移植受者心律失常和心率变异性的影响。方法:纳入2020年8月至2023年8月期间接受肾移植的27例糖尿病患者。HbA1c为bb0 8%的患者接受依帕列净治疗。在开始使用恩帕列净之前和一年后分别进行24小时动态心电图监测。由一名心脏病专家评估动态心电图,比较恩格列净治疗前后一年的室性异位搏(VEB)和室上异位搏(SEB)心律失常和心率变异性参数。结果:27例患者完成研究,患者平均年龄为56.1±10岁。男性15例(55.6%)。从移植到开始使用恩帕列净的平均持续时间为62.8±46.2个月。随访中,HbA1c由8.2%降至7.7%(P = 0.075),尿蛋白/肌酐比值由0.437±0.428降至0.267±0.146 gr/g (P = 0.056),血小板计数显著升高(P = 0.004)。治疗一年后,患者veb和seb的数量较治疗前减少。治疗前分别为173.5±460.8和514.8±265次,治疗后分别为125.1±231.7和125.1±231.7次,但无统计学意义(P < 0.05)。心率变异性参数无明显变化(P < 0.05)。veb、seb与心脏炎症指标无显著相关性(P < 0.05)。结论:本研究首次探讨了恩帕列净对糖尿病ktr患者心律失常和心率变异性的影响。恩帕列净对ktr患者的心律失常和心率变异性无显著影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信